Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 3/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21933954 | 0.89 | CHRM5 (0.33) | ACHECHRM5ADRA2C | |
| SCHEMBL21933962 | 0.89 | CHRM5 (0.33) | ACHECHRM5ADRA2C | |
| SCHEMBL21934606 | 0.89 | CHRM5 (0.33) | ACHECHRM5ADRA2C | |
| SCHEMBL23594252 | 0.86 | ACHE (0.35) | ACHECHRM5ADRA2C | |
| SCHEMBL26804417 | 0.84 | CCR2 (0.34) | HSD11B1ALDH1A1HRH3ACHECHRM5 | |
| SCHEMBL21934666 | 0.84 | ACHE (0.40) | HSD11B1ALDH1A1KDM4EHRH3ACHE | |
| SCHEMBL24837126 | 0.84 | CHRM5 (0.50) | KDM4EHRH3ACHECHRM5ADRA2C | |
| SCHEMBL23594068 | 0.82 | ACHE (0.35) | HSD11B1ACHECHRM5ADRA2C | |
| SCHEMBL23594135 | 0.82 | ACHE (0.35) | HSD11B1ACHECHRM5ADRA2C | |
| SCHEMBL23593980 | 0.82 | ACHE (0.35) | HSD11B1ACHECHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | HSD11B1 189/4885ALDH1A1 304/4885KDM4E 1268/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | HSD11B1 236/4885ALDH1A1 284/4885KDM4E 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.